4.4 Review

The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments

期刊

BIPOLAR DISORDERS
卷 11, 期 6, 页码 559-595

出版社

WILEY
DOI: 10.1111/j.1399-5618.2009.00737.x

关键词

atypical antipsychotics; bipolar disorder; guidelines; iatrogenesis; lithium; metabolic; monitoring; mood stabilizers; safety

向作者/读者索取更多资源

Objectives: Safety monitoring is an important aspect of bipolar disorder treatment, as mood-stabilising medications have potentially serious side effects, some of which may also aggravate existing medical comorbidities. This paper sets out the International Society for Bipolar Disorders (ISBD) guidelines for the safety monitoring of widely used agents in the treatment of bipolar disorder. These guidelines aim to provide recommendations that take into consideration the balance between safety and cost-effectiveness, to highlight iatrogenic and preventive clinical issues, and to facilitate the broad implementation of therapeutic safety monitoring as a standard component of treatment for bipolar disorder. Methods: These guidelines were developed by an ISBD workgroup, headed by the senior author (MB), through an iterative process of serial consensus-based revisions. After this, feedback from a multidisciplinary group of health professionals on the applicability of these guidelines was sought to develop the final recommendations. Results: General safety monitoring recommendations for all bipolar disorder patients receiving treatment and specific monitoring recommendations for individual agents are outlined. Conclusions: These guidelines are derived from evolving and often indirect data, with minimal empirical cost-effectiveness data available to provide guidance. These guidelines will therefore need to be modified to adapt to different clinical settings and health resources. Clinical acumen and vigilance remain critical ingredients for safe treatment practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Clinical Neurology

The Impact of Posttraumatic Stress Disorder on Pharmacologic Intervention Outcomes for Adults With Bipolar Disorder: A Systematic Review

Samantha E. Russell, Anna L. Wrobel, David Skvarc, Bianca E. Kavanagh, Melanie M. Ashton, Olivia M. Dean, Michael Berk, Alyna Turner

Summary: Comorbid PTSD may affect the pharmacologic treatment outcomes for adults with bipolar disorder. Further research is needed to inform pharmacotherapy selection and guidelines for individuals with comorbid bipolar disorder and PTSD.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2023)

Article Psychiatry

Childhood trauma and depressive symptoms in bipolar disorder: A network analysis

Anna L. Wrobel, Sue M. Cotton, Anuradhi Jayasinghe, Claudia Diaz-Byrd, Anastasia K. Yocum, Alyna Turner, Olivia M. Dean, Samantha E. Russell, Elizabeth R. Duval, Tobin J. Ehrlich, David F. Marshall, Michael Berk, Melvin G. McInnis

Summary: This study compared the networks of depressive symptoms among individuals with bipolar disorder with and without a history of childhood trauma. It found that depressed mood consistently emerged as a central symptom regardless of childhood trauma history. Among individuals with a history of childhood trauma, feelings of worthlessness emerged as a key symptom in the network of self-reported depressive symptoms. These findings provide insights into the impact of childhood trauma on depressive symptoms in bipolar disorder.

ACTA PSYCHIATRICA SCANDINAVICA (2023)

Article Substance Abuse

Diagnostic accuracy for self-reported methamphetamine use versus oral fluid test as the reference standard in a methamphetamine-dependent intervention trial population

Gregory Carter, Matthew J. Spittal, Linda Glowacki, Dimitri Gerostamoulos, Paul Dietze, Barbara Sinclair, Shalini Arunogiri, Michael Berk, Dan I. Lubman, Victoria Manning, Peter Higgs, Brendan Quinn, Amanda Baker, Olivia M. Dean, Alyna Turner, Rebecca McKetin

Summary: The aim of this study was to estimate the negative predictive value (NPV) of self-reported non-use of methamphetamine compared with an oral fluid reference standard for treatment of methamphetamine dependence. The findings suggest that self-report of no recent methamphetamine use is sufficiently accurate to be clinically useful in treatment settings.

ADDICTION (2023)

Review Biochemistry & Molecular Biology

Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis

Bruna Panizzutti, David Skvarc, Sylvia Lin, Sarah Croce, Alcy Meehan, Chiara Cristina Bortolasci, Wolfgang Marx, Adam J. Walker, Kyoko Hasebe, Bianca E. Kavanagh, Margaret J. Morris, Mohammadreza Mohebbi, Alyna Turner, Laura Gray, Lesley Berk, Ken Walder, Michael Berk, Olivia M. Dean

Summary: Minocycline has been found to have anti-inflammatory, antioxidant, and anti-apoptotic properties, which has led to a renewed interest in using it as an adjunctive treatment for psychiatric and neurological conditions. A systematic review and meta-analysis of the available data from clinical trials using minocycline was conducted, showing limited and difficult to interpret results for most conditions, but suggesting an overall benefit for using minocycline as an adjunctive treatment for schizophrenia.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Editorial Material Psychiatry

Biomarkers in psychiatric disorders: status quo, impediments and facilitators

Michael Berk

WORLD PSYCHIATRY (2023)

Article Pharmacology & Pharmacy

Risk of antidepressant initiation among users of cardiovascular agents and metformin. Findings from the Trondelag Health Study (HUNT) and Norwegian Prescription Database (NorPD), Norway

Ivana Bojanic, Ottar Bjerkeset, Lana J. Williams, Michael Berk, Johan Hakon Bjorngaard, Erik R. Sund, Hege Sletvold

Summary: This study examined the relationship between the use of cardiovascular drugs and metformin and the risk of initiating antidepressant use. The findings suggest that ARBs and CCBs as monotherapy may reduce the risk, while ASA or statins as polytherapy may also decrease the risk. However, the limitations in the study design may introduce bias.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2023)

Article Psychiatry

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders

Dhamidhu Eratne, Matthew Kang, Charles Malpas, Steve Simpson-Yap, Courtney Lewis, Christa Dang, Jasleen Grewal, Amy Coe, Hannah Dobson, Michael Keem, Wei-Hsuan Chiu, Tomas Kalincik, Suyi Ooi, David Darby, Amy Brodtmann, Oskar Hansson, Shorena Janelidze, Kaj Blennow, Henrik Zetterberg, Adam Walker, Olivia Dean, Michael Berk, Cassandra Wannan, Christos Pantelis, Samantha M. Loi, Mark Walterfang, Samuel F. Berkovic, Alexander F. Santillo, Dennis Velakoulis, MiND Study Grp

Summary: This study investigated the diagnostic utility of blood biomarkers of neuronal injury, specifically neurofilament light, in differentiating neurodegenerative disorders from primary psychiatric disorders (PPD). The results showed that neurofilament light could accurately distinguish behavioral variant frontotemporal dementia (bvFTD) from PPD. Large reference data sets and models were used to interpret individual levels, and slightly higher neurofilament light levels were found in bipolar affective disorder (BPAD) compared to controls and treatment-resistant schizophrenia (TRS).

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Clinical Neurology

Patterns of pharmacotherapy for bipolar disorder: A GBC survey

Balwinder K. Singh, Anastasia Yocum, Rebecca E. Strawbridge, Katherine E. Burdick, Caitlin T. Millett, Amy H. Peters, Sarah Sperry, Giovanna Fico, Eduard Vieta, Norma Verdolini, Ophelia Godin, Marion Leboyer, Etain F. Bruno, Ivy J. Tso, Brandon G. Coombes, Melvin A. McInnis, Andrew H. Nierenberg, Allan M. Young, Melanie Ashton, Michael J. Berk, Lana Williams, Kamyar N. Keramatian, Lakshmi J. Yatham, Bronwyn M. Overs, Janice Fullerton, Gloria B. Roberts, Philip A. Mitchell, Ole C. Andreassen, Ana P. Andreazza, Peter Zandi, Daniel M. Pham, Joanna A. Biernacka, Mark Frye, FACE BD Collaborators, Global Bipolar Cohort Collaborativ

Summary: This study investigated pharmacotherapeutic treatment patterns in multiple cohorts of individuals with bipolar disorder (BD) in North America, Europe, and Australia. Mood-stabilizing anticonvulsants, second-generation antipsychotics, and antidepressants were the most commonly prescribed medications. There were significant differences in prescription practices among different geographic regions.

BIPOLAR DISORDERS (2023)

Review Psychiatry

Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management

Michael Berk, Ole Kohler-Forsberg, Megan Turner, Brenda W. J. H. Penninx, Anna Wrobel, Joseph Firth, Amy Loughman, Nicola J. Reavley, John J. Mcgrath, Natalie C. Momen, Oleguer Plana-Ripoll, Adrienne O'Neil, Dan Siskind, Lana J. Williams, Andre F. Carvalho, Lianne Schmaal, Adam J. Walker, Olivia Dean, Ken Walder, Lesley Berk, Seetal Dodd, Alison R. Yung, Wolfgang Marx

Summary: Populations with common physical diseases are more likely to have major depressive disorder (MDD), and people with MDD are at a greater risk for physical diseases. This comorbidity is associated with worse outcomes, reduced treatment adherence, increased mortality, and higher healthcare utilization and costs. Shared genetic and biological pathways, as well as social and lifestyle factors, contribute to the high prevalence of comorbidity. Pharmacotherapies and psychotherapies are effective treatments, and lifestyle interventions and collaborative care models show promise for improving management.

WORLD PSYCHIATRY (2023)

Article Psychiatry

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions

Roger S. Mcintyre, Mohammad Alsuwaidan, Bernhard T. Baune, Michael Berk, Koen Demyttenaere, Joseph F. Goldberg, Philip Gorwood, Roger Ho, Siegfried Kasper, Sidney H. Kennedy, Josefina Ly-Uson, Rodrigo B. Mansur, R. Hamish McAllister-Williams, James W. Murrough, Charles B. Nemeroff, Andrew A. Nierenberg, Joshua D. Rosenblat, Gerard Sanacora, Alan F. Schatzberg, Richard Shelton, Stephen M. Stahl, Madhukar H. Trivedi, Eduard Vieta, Maj Vinberg, Nolan Williams, Allan H. Young, Mario Maj

Summary: Treatment-resistant depression is common and has serious public health implications. The lack of a consensus definition hampers accurate estimates of its prevalence and efforts to identify effective interventions, leading to heterogeneity in treatment decision-making and potentially compromising quality of care.

WORLD PSYCHIATRY (2023)

Article Medicine, General & Internal

Bipolar At-Risk Criteria and Risk of Bipolar Disorder Over 10 or More Years

Aswin Ratheesh, Dylan Hammond, Michael Watson, Jennifer Betts, Emma Siegel, Patrick Mcgorry, Michael Berk, Susan Cotton, Andrew Chanen, Barnaby Nelson, Andreas Bechdolf

Summary: The study found that patients meeting bipolar at-risk (BAR) criteria were more likely to transition to bipolar disorder (BD) over a decade after diagnosis compared to patients not meeting the criteria. This suggests that patients meeting BAR criteria may require longer-term monitoring and support.

JAMA NETWORK OPEN (2023)

Article Nutrition & Dietetics

Obesity and sarcopenic obesity characterized by low-grade inflammation are associated with increased risk for major depression in women

Julie A. Pasco, Michael Berk, Brenda Penninx, Natalie K. Hyde, Kara L. Holloway-Kew, Emma C. West, Mark A. Kotowicz, Kara B. Anderson, Adrienne O'Neil, Pamela G. Rufus-Membere, Lana J. Williams

Summary: This longitudinal study reports that women with both obesity and systemic inflammation are at increased risk of subsequent major depressive disorder (MDD). Future research should examine whether reducing the risk of depression in this metabolically unhealthy obesity type through lifestyle or medication interventions is possible.

FRONTIERS IN NUTRITION (2023)

Review Nutrition & Dietetics

Fiber intake and fiber intervention in depression and anxiety: a systematic review and meta-analysis of observational studies and randomized controlled trials

Hajara Aslam, Mojtaba Lotfaliany, Daniel So, Kirsten Berding, Michael Berk, Tetyana Rocks, Meghan Hockey, Felice N. Jacka, Wolfgang Marx, John F. Cryan, Heidi M. Staudacher

Summary: This study conducted a systematic literature review and meta-analysis to explore the effects of dietary fibers on depressive and anxiety outcomes. The results showed a negative correlation between fiber intake and depressive and anxiety outcomes in observational studies. However, current randomized controlled trials did not support the use of fiber supplementation for improving depressive or anxiety outcomes. Further research, including clinical trials in specific populations and using a wider range of fiber types, is needed.

NUTRITION REVIEWS (2023)

Article Psychiatry

Reduced mitochondrial respiratory capacity in patients with acute episodes of bipolar disorder: Could bipolar disorder be a state-dependent mitochondrial disease?

Anna Gimenez-Palomo, Mariona Guitart-Mampel, Ana Meseguer, Roger Borras, Francesc Josep Garcia-Garcia, Esther Tobias, Laura Valls, Xavier Alsina-Restoy, Gemma Roque, Ester Sanchez, Josep Roca, Gerard Anmella, Marc Valenti, Lorenzo Bracco, Helena Andreu, Sergi Salmeron, Lluc Colomer, Joaquim Radua, Norma Verdolini, Michael Berk, Eduard Vieta, Gloria Garrabou, Isabella Pacchiarotti

Summary: This study investigated mitochondrial respiration in patients with BD during mood episodes and found that there was a significant increase in maximal oxygen consumption capacity after clinical remission. This suggests that bioenergetic and mitochondrial dysregulation may be present in both manic and depressive phases of BD, and could potentially serve as biomarkers for illness activity and clinical response. Further research with larger samples is needed to confirm these findings.

ACTA PSYCHIATRICA SCANDINAVICA (2023)

Article Psychiatry

The Influence of Personality Disorder Symptoms on Treatment Outcomes in Bipolar Disorder: A Secondary Analysis of a Randomised Controlled Trial

Alessandra Sarmiento, Olivia M. Dean, Bianca E. Kavanagh, Mohammadreza Mohebbi, Michael Berk, Seetal Dodd, Sue M. Cotton, Gin S. Malhi, Chee H. Ng, Alyna Turner

Summary: This study explores how personality disorder influences pharmacological treatment outcomes in individuals with bipolar disorder. The findings suggest that maladaptive personality traits can lead to poorer treatment outcomes and comorbid personality disorder may add additional burden to treatment. Understanding the impact of personality disorder on bipolar disorder is important for personalized treatment options.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)

暂无数据